Uni-IP

🚀 The first and largest marketplace for university IP 🌐 19K+ techs from 20+ universities 🤖 Intelligent IP discovery & due diligence

[Uni-IP @uni_ip]

This is a truly unique approach not currently in trials. Monoclonal antibodies like prasinezumab are passive, immune driven approaches. Whereas this Hsp104 technology is an active, protein reverse and rescue approach. The potential to reverse disease pathology is exciting to see!

[Uni-IP @uni_ip]

⭐️SPOTLIGHT: A new approach to treat neurodegenerative diseases with potentiated Hsp104 prion disaggregase variants.

From Meredith Jackrel & James Shorter @Penn, this is a novel therapeutic approach for neurodegenerative diseases. 🚀
#ALS #Parkinsons #Huntington #Alzheimers

[Uni-IP @uni_ip]

A key challenge with protein therapeutics is off-target effects. Their recent research even shows they can enhance selectivity by tuning the Hsp104 pore loops, making it more effective against specific toxic proteins like alpha-synuclein and less likely to disrupt healthy ones.

[Uni-IP @uni_ip]

🌟 Introducing the Uni-IP Spotlight Series
We’ll be regularly highlighting standout university technologies—from cutting-edge therapeutics to breakthrough platforms—directly from our marketplace.
Follow along to discover the next big thing before anyone else. 👀
#Licensing

[Uni-IP @uni_ip]

If you care about university innovation, you’ll want to try this.
🔗 https://t.co/4hdZGOeo4X
Use promo code UNI-IP-MONTH1 for early access.
Let’s unlock the future hiding in plain sight.
#IP #Startups #LifeSciences #AI #TechTransfer #Innovation

[Uni-IP @uni_ip]

🚀 Introducing Uni-IP: the first and largest marketplace for university technologies with tailor-built diligence tools.
19K+ innovations from 20+ universities — all searchable, all in one place.
Let’s fix IP commercialization.
🧵👇

[Uni-IP @uni_ip]

Already live:
🌐 19,000+ technologies
🏛️ From 20+ universities
⚙️ Used by investors, tech transfer teams, researchers
We’re just getting started.